As Chuang et al. reported, miR-223-5p is associated with the development of SpAs [32] obesity, insulin resistance, atherosclerosis [33,34], and upregulation of the IL-17 pathway [34]; therefore, it could also represent a potential novel target as a modulator of inflammation and metabolism in PsA. Here, IL17A is linked to atherosclerosis.